Trial Profile
A Phase I Study of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified γδ T Cells in Patients With Newly Diagnosed Glioblastoma Multiforme Receiving Maintenance Temozolomide Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs INB-200 (Primary) ; Temozolomide; Temozolomide; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; First in man
- 14 Feb 2024 According to an IN8bio media release, the company announced a publication in Frontiers in Immunology.
- 22 Jan 2024 Planned End Date changed from 1 Jan 2025 to 31 Dec 2024.
- 22 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 31 Dec 2024.